Savira Signs Influenza License Agreement

Savira pharmaceuticals GmbH recently signed a license agreement with Roche.

Under the terms of the agreement, Savira will receive a non-disclosed one-time payment in return for a non-exclusive, world-wide license to a part of Savira’s influenza polymerase patent rights. The agreement relates to a previous collaboration between Roche and Savira, which was terminated recently.

About Savira

Savira pharmaceuticals GmbH – based in Vienna, Austria – is focusing on the design of novel, innovative influenza therapeutics using a rational, structure-based drug development approach. Savira follows the biotech business model, turning capital and public grants into the preclinical and clinical development of a portfolio of anti-influenza drug candidates. Savira thus strives to create a sustainable pipeline, generate value for shareholders, improve quality of life for people suffering from influenza, and add to the arsenal of antivirals thus improving influenza pandemic preparedness.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)